[A19-97] Olaparib (breast cancer) - Addendum to Commission A19-57
Last updated 16.01.2020
Commission awarded on 26.11.2019 by the Federal Joint Committee (G-BA).
Monotherapy of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer
Conclusion of dossier assessment A19-57 unchanged
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.